EMA and FDA extend confidentiality arrangements indefinitely
The EMA and the FDA have extended their confidentiality arrangements for human and veterinary medicinal products following the "positive experience" gained since the initial arrangements were signed in 2003.
The EMA and the FDA have extended their confidentiality arrangements for human and veterinary medicinal products following the “positive experience” gained since the initial arrangements were signed in 2003. Previously, the arrangements had been renewed in 2005 until 2010, but the latest development will see the cooperation continue indefinitely without the need for further renewal, according to a press statement.
The arrangements allow both agencies to exchange confidential information as part of their regulatory and scientific processes. The types of information covered relate to scientific advice, orphan drug designation, pediatric development, GMP and GCP, inspection planning and reports, marketing authorization procedures and subsequent changes to the marketing authorizations, together with post-marketing surveillance.
The types of medicines covered are those subject to evaluation or authorized under the centralized procedure, as well as medicines that are authorized at national level by EU member states and that are subject to official European Community arbitrations and referrals.
Cooperation between the two agencies has been increasing significantly during the past few years. Only last month, the agencies issued a call for candidates to take part in a joint GMP inspection pilot programme. In March, the agencies also agreed to accept a single orphan drug designation annual report.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
